Mass Tort Advertising Campaign
Power morcellator litigation centers on laparoscopic devices used during hysterectomies and myomectomies that, in women with undetected uterine cancer, can scatter malignant tissue throughout the abdominal cavity — a process known as upstaging. Manufacturers including Johnson & Johnson (Ethicon), Karl Storz, and LiNA marketed these devices widely before mounting safety concerns prompted significant regulatory action in 2014. The gap between how these devices were sold and what patients actually experienced is the core of the liability narrative.
For plaintiff firms, this tort represents a defined, identifiable claimant population with a medically documentable injury mechanism and named, well-resourced defendants. Paid social acquisition can surface women who underwent these procedures and later received an upstaged cancer diagnosis — a group that may not yet know their surgical history is legally relevant. That awareness gap is precisely where a well-structured Facebook and Instagram campaign creates value.
The litigation against power morcellator manufacturers is grounded in allegations that Ethicon, Karl Storz, LiNA, and others failed to adequately warn surgeons and patients that morcellation of an occult uterine malignancy could disseminate cancerous cells, dramatically worsening prognosis. The FDA's 2014 safety communication — which discouraged the use of laparoscopic power morcellators for the majority of women undergoing hysterectomy or myomectomy — serves as a critical inflection point in the case timeline. Procedures performed before that warning carry the strongest liability posture, as plaintiffs can argue defendants had reason to know of the risk and failed to act.
The central injury — upstaging of uterine cancer following morcellation — is both medically specific and emotionally resonant. A woman who underwent what she believed was a routine, minimally invasive procedure and later learned her cancer had been spread by the surgical device faces a concrete, traceable harm. That specificity makes intake qualification more straightforward than in many mass torts, and it gives creative teams a clear, honest story to tell in paid media without overpromising or obscuring the mechanism.
The creative challenge with power morcellator campaigns is reaching a population that is medically literate enough to remember a surgical procedure but may never have connected that procedure to a worsening cancer outcome. On Facebook and Instagram, this means leading with recognition — not alarm. Ad copy and video creative should help women identify the specific procedure name (hysterectomy or myomectomy), the laparoscopic approach, and the subsequent cancer diagnosis, in that order. The emotional core of the creative is not fear; it is the moment of recognition that something that happened in the operating room may have changed the course of their illness. That framing drives qualified clicks from women who have a real story to tell, and it filters out unqualified traffic before it reaches intake.
Audience targeting layers medical procedure interest signals with demographic targeting appropriate to the age ranges most commonly affected by uterine conditions requiring surgical intervention. Retargeting sequences can be used to move borderline responders — those who engaged but did not convert — through an educational funnel that helps them locate surgical records or recall procedure details before speaking with intake staff. Because this tort has a defined pre/post-2014 qualification threshold, intake scripts and landing page logic can be built to triage cases efficiently, keeping cost-per-qualified-lead manageable even in a borderline-status environment.
Mass Tort Ad Agency runs Power Morcellator campaigns on the same transparent model as every tort: actual Meta ad spend at cost plus a flat 15% management fee, a one-time $1,000 setup fee per tort, and $100 per signed retainer for CloudIntake qualification. No per-case markups, no lead resale, and the firm owns its ad account, pixel, creative, and claimant data.
We build, run, and qualify Power Morcellator claimant-acquisition campaigns end to end. Book a call and we'll walk you through the creative, audience, and intake plan.
Book a strategy call